We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Added Benefits and User Satisfaction with a Low-Dose Oral Contraceptive Containing Drospirenone: Results of Three Multicentre Trials.
- Authors
Bitzer, Johannes; Paoletti, Anna M.
- Abstract
The ethinylestradiol 20 μg/drospirenone 3 mg combined oral contraceptive (COC), administered in cycles of 21 days continuous use followed by a 7-day hormone-free interval (21/7) [Yasminelle®], has been proven to be an effective and well tolerated contraceptive with an acceptable bleeding pattern and good safety profile. In addition, the ethinylestradiol 20 ug/drospirenone 3 mg 21/7 COC prevents water-retention-related weight gain, and improves physical and emotional well-being, consistent with other drospirenone-containing COCs. In clinical studies, >85% of those who received the ethinylestradiol 20 μg/drospirenone 3 mg 21/7 COC were satisfied or very satisfied with this contraceptive. The positive attributes of the ethinylestradiol 20 μg/drospirenone 3 mg 21/7 COC: beyond contraceptive protection may have important implications for improving treatment compliance and reducing treatment discontinuation. Physical well-being stayed the same or improved during use of this COC in 56% and 34% of women, respectively. Emotional well-being stayed the same or improved in 71% and 20% of women, respectively.
- Subjects
ORAL contraceptives; GYNECOLOGIC drugs; PROGESTATIONAL hormones; WEIGHT gain; WELL-being; MENTAL health; MEDICAL equipment
- Publication
Clinical Drug Investigation, 2009, Vol 29, Issue 2, p73
- ISSN
1173-2563
- Publication type
Article
- DOI
10.2165/0044011-200929020-00001